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ABSTRACT 
 
OBJECTIVE: The objective of this selective evidence based medicine (EBM) review is to 
determine whether or not “Do injections of OnabotulinumtoxinA reduce migraine attack 
frequency in adults?” 
 
STUDY DESIGN: A systematic review of three peer-reviewed studies published between 2015 
and 2017. 
 
DATA SOURCES: One randomized controlled trial; one randomized, double-blind, placebo-
controlled clinical trial; and one observational, open-label, cohort study comparing frequency 
of migraine in adults when injected with OnabotulinumtoxinA (OBT-A). Based on their 
ability to answer the clinical question, articles were selected from PubMed and Cochrane 
Library.  
 
OUTCOME(S) MEASURED: All articles were based on patient oriented outcomes and 
focused on mean change from baseline in number of migraine attacks per month. Self-reported 
questionnaires and diaries kept by patients were used to track number of attacks.  
 
  RESULTS: One study conducted (Ranoux D, Martiné G, Espagne-Dubreuilh G, et al. The journal of    
  headache and pain. 2017;18(1): 75. doi:10.1186/s10194-017-0781-7) revealed a large treatment effect  
  and high response rate with 41 of 63 having ≥ 50% reduction in headache days per month with OBT-A  
  injection versus baseline (experimental event rate (EER)= 65.1%). In another study (Naderinabi B,  
  Saberi A, Hashemi M, et al. Caspian J Intern Med. 2017; 8(3): 196-204. doi:10.22088/cjim.8.3.196)  
  patients receiving OBT-A injections experienced a mean change from baseline of 12.4 and clinically  
  significant improvement (P=0.0001) versus a control group of 5.2 during a three month period. In a  
  third clinical trial (Hou M, Xie JF, Kong XP, et al. Toxins. 2015; 7(11): 4442-54.   
  doi:10.3390/toxins7114442) patients were injected with OBT-A during a four month interval  
  revealing a mean change in baseline of 7.2 to 3.5 headaches per month, and the study was clinically  
  significant with a p-value of <0.01.  
 
CONCLUSIONS: This review provides evidence from three separate studies that prophylactic 
injections with OBT-A greatly reduce the number of migraine attacks per month. Further 
research is warranted to provide more accurate time frames for efficacy and adverse effects 
(AE) compared to traditional prophylactic methods.   
 
KEY WORDS: OnabotulinumtoxinA, Botox®, migraine 




Migraine is a common, primary headache disorder with debilitating consequences 
affecting approximately 15% of the population world-wide.1,2  In 2016, the Global Burden of 
Disease Study classified migraine as the second leading cause of disability in patients less than 
50 years of age.2 Many patients are unable to carry on normal daily activities due to the 
symptoms associated with this neurovascular disorder which includes throbbing head pain, 
nausea, vomiting, photophobia, phonophobia, allodynia, fatigue, increased agitation, along with  
aura in many patients.1 Episodic attacks are common, but some patients may be diagnosed with 
chronic migraine (CM) when attacks frequently occur and pain is relentless to the point that 
prophylactic drugs are needed to function in normal daily activities.2 With a disease process 
affecting and interfering with so many across the globe, a definite need for preventative 
measures exists that allow patients to carry on their lives as normal without AE commonly seen 
with the most frequently used preventative medications on the market to date.  
Currently, the most widely accepted theory of migraine etiology is overstimulation of 
trigeminal ganglion nerves and a resultant release of neuropeptides.3 Overflow of neuropeptides 
ultimately leads to neurogenic inflammation and is believed to result in the neuronal 
overstimulation which causes the throbbing head pain associated with migraines and its 
associated symptoms.3 The mechanism of action with injections of OBT-A is thought to be an 
inhibition of trigeminal nerve overstimulation blocking the release of neuropeptides, therefore 
preventing the neurogenic inflammation that would have ultimately occured.1  
The most common, current therapies used for migraine prophylaxis are drugs used for 
other comorbid conditions. Use of these therapies for migraine is dependent on factors such as 
age, sex, current status of premorbid conditions, and is reliant on classes and medications such 
as beta blockers (e.g., propranolol and metoprolol), antidepressants (e.g., amitriptyline and 
venlafaxine), anticonvulsants (e.g., topiramate and valproate), or CGRP (calcitonin gene-related 
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peptide) antagonists (e.g., galcanezumab, fremanezumab, and/or erenumab).4 Inclusion or 
exclusion of patient conditions, current dosages, and AE must all be taken into consideration 
when prescribing these for migraine. Most of these must be taken on a daily basis while 
injections of OBT-A can be administered every 3 months,4 and many of the AE seen with 
traditional therapies have not been experienced in OBT-A injection trials to date.1,5  
In 2017, there were an estimated 1.2 million emergency department (ED) visits as a result 
of migraine,6 compounding the issue of long ED wait times seen around the globe. It has also 
been estimated that migraine costs are in excess of $20 million United States dollars (USD) 
annually.7 An opportunity exists for healthcare providers to introduce new methods of migraine 
prophylaxis that not only allow patients a better quality of life (QOL) but also reduces 
healthcare costs and cuts back on emergency department overcrowding. OBT-A injections have 
shown to be effective in multiple trials at a range of three to six months.8 This provides a 
possible solution to both of these issues along with far less AE, leading to better patient-
oriented outcomes. This systematic review evaluates the use of OBT-A injections to reduce the 
frequency of attacks many migraine sufferers experience. 
OBJECTIVE 
 
The objective of this selective evidence based medicine (EBM) review is to determine 




This paper assesses the effectiveness of OBT-A injections ability to produce a mean 
change in baseline of migraine attack frequency as measured by diaries kept by patients and 
self-reported questionnaires in adults ages 17-75 suffering from migraine. The following 
studies were used in this review: 1) a randomized controlled trial; 2) a randomized, double-
blind, placebo-controlled clinical trial; 3) an observational, open-label, cohort study. All three 
studies were used to address the proposed clinical question and focused on patient-oriented 
                     Allen, OBT-A Injections and Migraine Frequency 3 
 
outcomes. 
Keywords, “OnabotulinumtoxinA, Botox®, and migraine” were used searching 
PubMed and Cochrane Library Database for articles published in English. All articles were 
published in peer-reviewed journals over the last 10 years, and statistics were reported using 
p-values or experimental event rate (EER).  Inclusion criteria for article selection included: 
randomized controlled trial (RCT), articles published within the last 10 years, and those 
published in English; exclusion criteria included studies involving: only pediatrics, only 
acupuncture, and only Botox®.  
 Table 1 - Demographics and Characteristics of included studies5,8,1 
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 OUTCOMES MEASURED 
 
The outcomes measured were all patient-oriented and focused on a mean change from 
baseline in the number of migraine attacks individuals suffered during a predetermined time 
interval. Quantities of OBT-A injected and time periods observed all varied between trials. 
Details such as injection techniques, site of injections, intensity and duration of headaches, and 
associated symptoms were some specifics measured but attack frequency with a mean change 
from baseline in number of migraine attacks per month, measured by diaries kept by patients and 
self-reported questionnaires collected at pre-determined times, was the subject investigated from 
each article for this review. 
Ranoux et al. injected up to 150U of OBT-A per session during a two month span and 
considered patients responsive if having  ≥ 50% reduction of headache days per month after two 
consecutive, efficacious injection cycles.5 In the trial completed by Naderinabi et al., a total of 
155U were injected in test subjects and compared number of headache days with a control group 
using a placebo during a three month interval.8 Hou et al. injected a total of 25U per session and 
recorded the number of headache days per month over a four month interval and compared this 
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with a control group which was given a placebo.1  
RESULTS 
 
Ranoux et al. conducted an observational, open-label, cohort study through the Teaching 
Hospital of Limoges, France.5 Sixty-three patients were considered eligible and selected based 
on the International Headache Society (IHS) criteria for CM.5 Once selected, patients underwent 
an adaptive phase where the most appropriate injection site was determined based on the pain 
experienced by an individual during a CM attack.5 Patients then underwent an observation 
period which began eight weeks before the first effective dose, and ended eight weeks after the 
second, consecutive effective or ineffective dose.5 During both of these phases, patients kept a 
headache diary and recorded days which they had an attack.5 Patients were allowed to continue 
use of abortive medications, e.g., triptans, as needed.5  
Patients were injected to the corrugator, temporalis, and/or trapezius muscles with 70U of 
OBT-A if their pain was determined to be limited to the myofascial muscles during the adaptive 
phase and 150U if muscle groups of both the head and neck were involved.5 Patients were 
considered to be responsive to treatments if they had ≥50% reduction of headache frequency 
after two consecutive injection cycles.5 Of the 63 patients with intention to treat (ITT), 57 were 
able to complete the trial and 41 of those were considered responsive to treatment while 16 
patients reported that they were non-responsive to treatment (EER = 65.1%).5  








63 41 16 6 65.1% 
 
In 29 of the 41 responders, ≥ 70% reduction in headache day frequency was achieved and 
9 patients reported having ≤1 headache day per month.5 Among responders, 28 of the 41 were 
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accustomed to triptan abortive therapy and 81% reported reduced need of such drugs during the 
three to four month duration of action OBT-A injections provided.5 Patient satisfaction was 
particularly high, reported as being an 8.6 on a 0-10 scale.5 The only AE subjects reported was 
myalgia to the trapezius muscle which was described as being severe with the initial injection 
but subsequent doses were described as being minimally noticeable.5 In contrast to this, the site 
found to be most responsive to injections was the trapezius muscle with 38 of 41 (92.7%) 
responders finding efficacy at this site.5 
Table 3: Secondary Outcome Results5 
 Responders (N=41 Total) Percentage  
≥ 70% reduction of headache 
day frequency 
29 of 41 71% 
Reporting ≤ 1 headache per 
month 
9 of 41 22% 
Reduced need of abortive 
therapy (Triptans) 
28 of 41 81% 
Patient satisfaction (0-10 scale) Lowest 6.5, Highest 10 86% 
Most effective injection site 
(Trapezius muscle) 
38 of 41 92.7% 
 
This study provides data to support the proposed claim that OBT-A injections 
prophylactically reduce the number of headache days suffered by those diagnosed with 
migraines because of the large number of patients claiming response to treatment. Limitations of 
this trial include: generalizability being limited due to the small number of patients used in the 
trial, a lack of control or placebo being used, individual ages of patients are not detailed, and too 
little information is given to calculate the treatment effect. Based on outcomes of this study, 
there is evidence to support the use of OBT-A injections to reduce the number of headache days 
per month for those diagnosed as migraine sufferers.  
In the study piloted by Naderinabi et al., a randomized controlled trial (RCT) was held at 
the Guilan Pain Clinic, North of Iran.8  One hundred sixty-two patients were found eligible based 
on the International Classification and of Headache Disorders 3rd edition (ICHD-3) and selected 
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based on inclusion and exclusion criteria shown in Table 1.8 This study focused on comparing 
the treatment effects of patients injected with OBT-A, acupuncture techniques of traditional 
Chinese medicine (TCM), and a control group given sodium valproate 500mg/day for three 
months.8 Fifty patients were randomly placed into each group for a total of 150, leaving 12 who 
dropped out due to compliance issues unrelated to AE.8 All 150 patients completed the three 
month trail and were allowed to abortively treat their acute attacks with Novafen.8 All 50 patients 
who were injected with OBT-A were injected by the same injector who followed protocol of the 
phase III Research Evaluating Migraine Prophylaxis Therapy I (PREEMPTI).8 Each patient was 
given a total dose of 155U injected to the facial and peri-cranial muscle trigger zones.8 A 
physician who was blinded to treatment types per group completed an evaluation of each patient 
in each group at one month intervals for three months. Evaluations included the number of 
headache days per month, abortive medication use, and AE.8 By excluding patients who had 
taken traditional prophylactic medications within the past three months,8 a higher degree of 
validity could possibly be attributed to statistics analyzed during this trial. 
At baseline (T0), the group receiving OBT-A injections had an average of 23.6 headache 
days per month.8 The changes trended in the OBT-A group from 10.8 at the end of month one 
(T1), 9.7 after month two (T2), and 13.1 at the end of month three (T3)8 with the mean change 
from baseline at 10.5. This reveals a large treatment effect and a greater mean change from 
baseline than the control group which was 6.2 and trended at 19.3 (T0), 15.8 (T1), 13.4 (T2), and  
13.1 (T3).8 The p-values between groups at T0 was insignificant at (p= 0.072), with p < 0.05 
being statistically significant, but were significant at T3 (p=0.0001) and indicates the estimate of 
treatment effect is precise.8 
Table 4: Headache Days/Month and Trends in Mean Change from Baseline8  




OBT-A 23.6 10.8 9.7 13.1 12.4 





19.3 15.8 13.4 13.1 5.2 
Significance of 
Mean Change   
P=0.072   P=0.0001  
 
The average number of times patients needed acute abortive therapy per month was also 
reduced among patients injected with OBT-A from an average of 17.76 (T0) to 6.32 (T3), 
although this patient group had the greatest increase for drug therapy at T3.8 Nausea and 
vomiting was found to be insignificant (p > 0.05) among groups at T2 but at T3 those injected 
with OBT-A had a significantly higher rate (p=0.027).8 Both of these facts provide evidence for 
the half-life and therapeutic effects of OBT-A being limited to this period of time. The most 
common AEs reported with OBT-A were ptosis and facial asymmetry although this study 
regarded treatments as safe with very low complication rates, agreeing with prior studies.8 
 Table 5: Comparison of Side Effects8 
Test Group  T2 T3 
OBT-A p > 0.05 p=0.027 
Control Group (Sodium 
Valproate) 
p > 0.05 p > 0.05 
 
This study provides evidence of clinical importance supporting the claim that OBT-A 
injections do prophylactically reduce the number of headache days per month in migraine 
sufferers. The statistical analysis provided indicates the estimate of treatment effect is precise and 
strengthens this study.  Generalizability is limited while adding validity to the study due to 
patients suffering from medication overuse, opioid abuse, a past history of prophylactic drug use 
in the past three months, or a past history of OBT-A injections being excluded.   
In the randomized, double-blind, placebo-controlled clinical trial carried out by Hou et al. 
at the Department of Neurology and Pain Treatment, Gansu Province People Hospital in China, 
subjects (n=102) were enrolled according to inclusion and exclusion criteria documented in 
Table 1 and examined to determine the effects of OBT-A injections on migraine attacks at 
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baseline and the following four month period.1 It involved investigating effects among three 
groups: 1) 25U of OBT-A injected at fixed-site locations in the most common muscular trigger 
zones (n=41); 2) acupuncture that included OBT-A injections in common sites used in 
traditional Chinese medicine (n=42); and 3) a placebo group injected with 0.9% normal saline 
(n=19).1 The trial focused on attack frequency but also included other factors such as intensity, 
duration, and associated symptoms.1 Attacks were self-recorded by patients for one month prior 
to the first injection and four months afterward in a detailed diary reviewed monthly by 
investigators who had no awareness of the type of injection used per group.1  
Hou et al. provided data to support the claim that OBT-A injections produce a large 
decrease in frequency of migraine attacks during a four-month interval when compared with 
placebo, regardless if fixed-site or acupuncture injections were used.1 At baseline, the group 
injected with OBT-A at fixed-site locations suffered a mean of 7.5 migraine attacks per month, 
4.0 at the end of month one, 3.8 after month two, 3.6 after month three, and 3.7 after month 
four.1 This reveals a p-value of clinical significance (p < 0.01) compared with placebo which 
reported 7.5 attacks per month at baseline, 7.4 after month one, 7.1 after month two, 7.2 after 
month three, and 7.4 after month four.1  
Table 6: Headache Frequency/Month and Trends in Mean Change from Baseline1  












OBT-A 7.2 4.0 3.8 3.6 3.7 3.5 




     P<0.01 
 
While three of 41 (7%) injected with OBT-A at fixed-sites experienced AEs involving 
self-resolving, unilateral eye ptosis lasting from three to five days, 35 of the 41 subjects (85%) 
with fixed-site injections recorded reductions in migraine frequency during the four month 
period and nine of those reported to be attack free (22%).1 One patient complained of injection 
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site discomfort that dissipated in less than 24 hours.1 This study concurs with previous studies 
that OBT-A injections are safe, tolerable, and effective in the prophylaxis of migraine attacks 
with far fewer AE when compared to other drugs more commonly used.  
 
Table 7: Ratio of Migraine Frequency in OBT-A and AE1 
Test Group Ratio 
of 
Patients  











9 of 41 22% 
AE (Eye ptosis)  3 of 41 7% 
 
Several factors may have affected the outcome of this study including the small number 
of subjects investigated and the disproportionate number of females to males; such factors 
should be taken into consideration when referencing this study. Generalizability of the trial is 
limited due to excluding patients who: may be at risk with exposure to OBT-A, have a pre-
existing medical condition interfering with neuromuscular function, pathological conditions 
which may contribute to migraine, current drug or alcohol abuse, and/or patients who were 
pregnant or breastfeeding.1 Taking these factors into consideration, this trial does relate to and 
provide evidence answering the clinical question that OBT-A injections do reduce migraine 
attack frequency in adults.   
  DISCUSSION 
 
Although rare, the most common AEs with OBT-A injections for CM include neck pain 
(9%) at injection sites and headache (5%).4 The only contraindication to OBT-A injection is 
current infection at injection site and hypersensitivity to previous administration; a black-box 
warning does exist in the United States for botulinum toxin effects which could spread from the 
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site of injection to distant locations.4  Total dosage recommended is up to 155U administered 
every 12 weeks.4 
To date, the most common prophylactic drugs used for migraine attacks include 
prescription drugs such as beta blockers, antidepressants, and anticonvulsants, each having 
many more AE than studies have found OBT-A injections result in, and pre-existing 
comorbidities requiring use of such drugs must be factored in when prescribing these 
medications.1,7,9 Compounding this issue is the fact that many migraine sufferers struggle with 
many of the AEs produced by the current preventative therapies prior to beginning treatments.6 
The AE produced by OBT-A injections in all three studies were temporary and self-resolved, 
aligning with previous research.1,5,8 
The studies reviewed in this article provide evidence supporting the use of OBT-A 
injections to prophylactically reduce the frequency of migraine while promoting effective 
patient-oriented outcomes with far less AE seen with currently approved medications. Whether 
episodic or chronic in nature, migraine headaches place a burden on and alter daily activities in 
millions of sufferers world-wide annually.6 These facts provide healthcare providers and 
researchers the opportunity to investigate and intervene with more effective treatments such as 
OBT-A injections.   
  CONCLUSION 
The three articles reviewed provide sufficient data supporting the use of OBT-A 
injections to provide prophylaxis in both episodic and CM attacks in adults. The use of a 
placebo and a control group in the studies by Hou et al.1 and Naderinabi et al.,8 respectively, 
provide clinical and statistical evidence that there is significant reduction in frequency of 
migraine headaches per month.  While the research conducted by Ranoux et al.5 does not use a 
placebo or control group, their use of responders versus non-responders to treatment may in fact 
yield a more accurate figure due to the exclusion of the possibility of a placebo effect.  
With regards to improvement among the trials, all three would benefit from having 
                     Allen, OBT-A Injections and Migraine Frequency 12 
 
larger numbers of subjects studied over longer time periods of time. A more recent study by 
Santoro et al.10 makes use of smartphone technology which may improve outcomes with both of 
these factors. By selecting a larger subject field and including a greater variety of race and 
ethnicity, more concrete evidence would be obtained in regards to OBT-A’s half-life, 
therapeutic effects, and AE.
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